Do analysts agree on SAGE Therapeutics (Sage) stock's price target?
According to analysts' consensus price target of $70.63, Sage Therapeutics has a forecasted upside of 81.4% from its current price of $38.93. Sage Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Who buys Sage stock?
SAGE stock was acquired by a variety of institutional investors in the last quarter, including Cooper Financial Group, and State of Alaska Department of Revenue. Company insiders that have bought Sage Therapeutics stock in the last two years include Albert Robichaud, Barry E Greene, James M Frates, and Jeffrey M Jonas.
How much dividend does Sage Group plc (SGE) pay?
The Sage Group plc ( LON:SGE ) has announced that it will pay a dividend of UK£0.12 per share on the 10th of February...
What does brightpearl acquisition mean for Sage Group plc?
The acquisition of Brightpearl, in which Sage already has a 17% minority stake, accelerates Sage’s strateg The Sage Group plc ( LON:SGE ) has announced that it will pay a dividend of UK£0.12 per share on the 10th of February...
Is SAGE a good stock?
Out of 11 analysts, 2 (18.18%) are recommending SAGE as a Strong Buy, 2 (18.18%) are recommending SAGE as a Buy, 7 (63.64%) are recommending SAGE as a Hold, 0 (0%) are recommending SAGE as a Sell, and 0 (0%) are recommending SAGE as a Strong Sell. What is SAGE's earnings growth forecast for 2022-2024?
Is Sage Therapeutics a good buy?
Sage Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 6 buy ratings, 8 hold ratings, and no sell ratings.
Why is SAGE stock dropping?
Case in point: Sage Therapeutics (SAGE) shares dropped 24% since Monday, after the company released disappointing late-stage results for zuranolone, the major depressive disorder (MDD) drug candidate the company is collaborating on with Biogen.
Will Sage Therapeutics Stock go up?
The 20 analysts offering 12-month price forecasts for SAGE Therapeutics Inc have a median target of 54.50, with a high estimate of 105.00 and a low estimate of 36.00. The median estimate represents a +59.22% increase from the last price of 34.23.
Is SAGE a buy Zacks?
The Zacks database contains over 10,000 stocks. All of those stocks are classified into three groups: Sector, M Industry and X Industry....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy25.08%2Buy18.56%3Hold10.15%4Sell5.79%2 more rows
What does Sage Therapeutics do?
Sage is committed to developing new medicines to treat life-altering brain health disorders.
When did SAGE Therapeutics go public?
July 18, 2014Sage Therapeutics is traded on the NASDAQ Global Market under the ticker symbol SAGE and its CUSIP number is 78667J 108. When did Sage Therapeutics go public? Sage Therapeutics' initial public offering (IPO) occurred on July 18, 2014.
Who is the CEO of Sage Therapeutics?
Barry E GreeneSage Therapeutics / CEO
Does Sage Therapeutics drug test?
Does Sage drug test? No it does not.
Should I buy or sell Sage Therapeutics stock right now?
17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently...
What is Sage Therapeutics' stock price forecast for 2022?
17 Wall Street analysts have issued twelve-month price objectives for Sage Therapeutics' stock. Their forecasts range from $37.00 to $85.00. On ave...
How has Sage Therapeutics' stock performed in 2022?
Sage Therapeutics' stock was trading at $42.54 on January 1st, 2022. Since then, SAGE shares have decreased by 18.7% and is now trading at $34.58....
When is Sage Therapeutics' next earnings date?
Sage Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Sag...
How were Sage Therapeutics' earnings last quarter?
Sage Therapeutics, Inc. (NASDAQ:SAGE) issued its earnings results on Tuesday, May, 3rd. The biopharmaceutical company reported ($2.07) EPS for the...
Who are Sage Therapeutics' key executives?
Sage Therapeutics' management team includes the following people: Mr. Barry E. Greene , Pres, CEO & Director (Age 59, Pay $1.25M) ( LinkedIn Pro...
Who are some of Sage Therapeutics' key competitors?
Some companies that are related to Sage Therapeutics include Grifols (GRFS) , Maravai LifeSciences (MRVI) , Legend Biotech (LEGN) , Sarepta The...
What other stocks do shareholders of Sage Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA) , A...
What is Sage Therapeutics' stock symbol?
Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."
When will Sage Therapeutics release its earnings?
How much does Sage Therapeutics make?
Sage Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021. View our earnings forecast for Sage Therapeutics.
Who bought Sage Therapeutics?
Sage Therapeutics has a market capitalization of $2.82 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $606.07 million in net income (profit) each year or ($9.47) on an earnings per share basis.
Who is the CEO of Sage Group?
Company insiders that have bought Sage Therapeutics stock in the last two years include Albert Robichaud, Barry E Greene, James M Frates, and Jeffrey M Jonas. View insider buying and selling activity for Sage Therapeutics or or view top insider-buying stocks.
Where is Sage located?
Steve Hare, CEO of Sage Group commented: “As the economic environment improves, optimism amongst our customers is increasing and as is their confidence to capitalize on the opportunities ahead.
Is Sage Net Zero?
Sage is leveraging the Amazon Web Services (AWS) Canada (Central) Region in Montreal, setting up its first local presence and adding to the seven other regions where it operates globally.
Premium Research for SAGE
Sage pledges business mentoring, advice and support for over 1.2 million people from underrepresented groups around the world, and commits to being Net Zero by 2040ATLANTA, June 24, 2021 (GLOBE NEWSWIRE) -- Today, Sage, the market leader in cloud business management solutions, launches its ambitious new sustainability and society strategy, Knocking Down Barriers. Sage’s goal is to tackle societal and economic inequality as well as support a new generation of diverse and sustainable businesses. S
Company Summary
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Signals & Forecast
SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions.
Support, Risk & Stop-loss
There are few to no technical positive signals at the moment. The Sage Therapeutics stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Is Sage Therapeutics stock A Buy?
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Insiders are very positive buying more shares than they are selling in Sage Therapeutics
Sage Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
About Sage Therapeutics
In the last 100 trades there were 1.28 million shares bought and 54.5 thousand shares sold. The last trade was done 7 days ago by Jonas Jeffrey M who sold 4 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
When is Sage 2021?
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
What is Sage's treatment for depression?
(NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in a fireside chat at SVB Leerink’s 3rd Annual CNS Forum on June 29th at 4:15pm ET.
